Major Ingredients

Each metered dose (Puff) contains Salmeterol BP 25 mcg as Salmeterol Xinafoate and Fluticasone Propionate BP 250 mcg.

Major Functionality

This Inhaler is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short acting beta-2- agonist or, Patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.